Patient characteristics and outcome of treatment
| Patient no. . | Age, y/ sex . | Diagnosis/ stage/histo . | Site(s) of disease . | Status before Tx . | PD after Tx (day) . | Days to DLI . | DLI dose (CD3+ cells/kg) . | IFNα . | aGVHD grade . | cGVHD . | Response . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 40/F | BC/IIB | lung, pleura, skin | PD | + 232 | + 258 | 0.9 × 107/kg | – | I (+ 14) | – | – | 1003+ SD |
| 2 | 52/F | BC/IIA | liver, lung, pleura, bone, BM | PD | + 70 | + 148 | 1 × 107/kg | – | – | – | – | 464 death, PD |
| 3 | 46/F | BC/IIIB | nodes, skin | PD | + 60 | + 111 | 2 × 107/kg | – | II (+ 122) | extensive | PR (+ 225) | 490 death, PR GVHD |
| 4 | 40/F | BC/IIB | bone, BM | SD | + 120 | + 132 | 1 × 107/kg | – | – | – | – | 437+ PD |
| + 171 | 5 × 107/kg | |||||||||||
| + 205 | 1 × 108/kg | |||||||||||
| 5 | 36/F | BC/IIA | lung, bone, nodes | SD | + 41 | – | – | – | – | – | – | 109 death, PD |
| 6 | 44/F | BC/IIA | bone, BM, pleura | PD | + 69 | + 131 | 2 × 107/kg | – | II (+ 206) | extensive | PR (+ 227) | 417+ PR |
| + 164 | 1 × 108/kg | yes | ||||||||||
| 7 | 60/F | RCC/III clear cell | lung, CNS | PD | + 70 | + 367 | 1.2 × 107/kg | – | II (+ 102 and + 559) | extensive | PR (+ 117) | 820 death, PD |
| + 425 | 5 × 107/kg | – | ||||||||||
| + 474 | 1 × 108/kg | yes | ||||||||||
| 8 | 54/M | RCC/III clear cell | lung | PD | + 61 | – | – | – | II (+ 81) | limited | PR (+ 116) | 498+ PD |
| 9 | 44/M | RCC/IV clear cell | lung | PD | – | – | – | – | III (+ 89) | extensive | PR (+ 104) | 263 death, PR aspergillus |
| 10 | 48/F | RCC/IV clear cell | lung, CNS | PD | – | – | – | – | II (+ 12) | – | SD | 235+ SD |
| 11 | 18/M | RCC/III papillary | lung, bone, nodes, CNS | PD | + 30 | + 130 | 7 × 107/kg | – | – | – | – | 140 death, PD |
| 12 | 59/M | RCC/II clear cell | lung | SD | – | – | – | – | II (+ 130) | limited | PR (+ 189) | 208+ PR |
| 13 | 47/M | RCC/IV clear cell | lung | SD | – | – | – | – | II (+ 107) | extensive | SD | 194+ SD |
| Patient no. . | Age, y/ sex . | Diagnosis/ stage/histo . | Site(s) of disease . | Status before Tx . | PD after Tx (day) . | Days to DLI . | DLI dose (CD3+ cells/kg) . | IFNα . | aGVHD grade . | cGVHD . | Response . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 40/F | BC/IIB | lung, pleura, skin | PD | + 232 | + 258 | 0.9 × 107/kg | – | I (+ 14) | – | – | 1003+ SD |
| 2 | 52/F | BC/IIA | liver, lung, pleura, bone, BM | PD | + 70 | + 148 | 1 × 107/kg | – | – | – | – | 464 death, PD |
| 3 | 46/F | BC/IIIB | nodes, skin | PD | + 60 | + 111 | 2 × 107/kg | – | II (+ 122) | extensive | PR (+ 225) | 490 death, PR GVHD |
| 4 | 40/F | BC/IIB | bone, BM | SD | + 120 | + 132 | 1 × 107/kg | – | – | – | – | 437+ PD |
| + 171 | 5 × 107/kg | |||||||||||
| + 205 | 1 × 108/kg | |||||||||||
| 5 | 36/F | BC/IIA | lung, bone, nodes | SD | + 41 | – | – | – | – | – | – | 109 death, PD |
| 6 | 44/F | BC/IIA | bone, BM, pleura | PD | + 69 | + 131 | 2 × 107/kg | – | II (+ 206) | extensive | PR (+ 227) | 417+ PR |
| + 164 | 1 × 108/kg | yes | ||||||||||
| 7 | 60/F | RCC/III clear cell | lung, CNS | PD | + 70 | + 367 | 1.2 × 107/kg | – | II (+ 102 and + 559) | extensive | PR (+ 117) | 820 death, PD |
| + 425 | 5 × 107/kg | – | ||||||||||
| + 474 | 1 × 108/kg | yes | ||||||||||
| 8 | 54/M | RCC/III clear cell | lung | PD | + 61 | – | – | – | II (+ 81) | limited | PR (+ 116) | 498+ PD |
| 9 | 44/M | RCC/IV clear cell | lung | PD | – | – | – | – | III (+ 89) | extensive | PR (+ 104) | 263 death, PR aspergillus |
| 10 | 48/F | RCC/IV clear cell | lung, CNS | PD | – | – | – | – | II (+ 12) | – | SD | 235+ SD |
| 11 | 18/M | RCC/III papillary | lung, bone, nodes, CNS | PD | + 30 | + 130 | 7 × 107/kg | – | – | – | – | 140 death, PD |
| 12 | 59/M | RCC/II clear cell | lung | SD | – | – | – | – | II (+ 130) | limited | PR (+ 189) | 208+ PR |
| 13 | 47/M | RCC/IV clear cell | lung | SD | – | – | – | – | II (+ 107) | extensive | SD | 194+ SD |
Tx indicates transplantation; histo, histology; PD, progressive disease; SD, stable disease; BM, bone marrow; PR, partial remission; DLI, donor lymphocyte infusion; IFNα, interferon alpha; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; BC, breast cancer; RCC, renal cell cancer; CNS, central nervous system.